601 Genome Way
Suite 2001
Huntsville, AL 35806
United States
256 327 0566
https://serinatherapeutics.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Steven A. Ledger | Interim CEO & Director | 237,5k | S.O. | 1959 |
Dr. Tacey Viegas Ph.D. | COO & Secretary | 356,53k | S.O. | 1958 |
Dr. Randall W. Moreadith M.D., Ph.D. | Chief Scientific Officer | 433,88k | S.O. | 1955 |
Dr. Balkrishan Gill Ph.D. | Executive Chairman | S.O. | S.O. | 1965 |
Ms. Eun-Jae Park CPA | Interim CFO & Chief Accounting Officer | S.O. | S.O. | 1972 |
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama.
L’ISS Governance QualityScore de Serina Therapeutics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..